Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 526 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 526 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $27.54, for a total value of $14,486.04. Following the sale, the chief executive officer now directly owns 1,048,729 shares of the company’s stock, valued at $28,881,996.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.89, for a total value of $274,680.00.
• On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.56, for a total transaction of $62,561.20.
• On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.92, for a total transaction of $299,040.00.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $27.53 on Friday. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -14.26 and a beta of 1.10. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $27.67. The stock’s 50 day simple moving average is $23.21 and its two-hundred day simple moving average is $22.00.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ELVN shares. Robert W. Baird began coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Finally, Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th.

Institutional Trading of Enliven Therapeutics

Large investors have recently made changes to their positions in the business. Quest Partners LLC raised its position in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares during the period. American Century Companies Inc. boosted its stake in shares of Enliven Therapeutics by 44.7% during the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after purchasing an additional 8,540 shares during the period. EntryPoint Capital LLC bought a new position in Enliven Therapeutics during the 1st quarter valued at about $167,000. Finally, SG Americas Securities LLC bought a new stake in Enliven Therapeutics in the third quarter worth about $256,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.